Today’s article discusses Johnson & Johnson and whether its stock is done moving up for the moment. Here’s what they had to say, “Johnson & Johnson’s stock has come down slightly from its peak value and has been more or less stable for a while in absence of any meaningful triggers. Unless and until some good reliable news comes out regarding the company’s drug pipeline, we believe that further stock price appreciation is unlikely.” To read more, CLICK HERE.